immunophenotype of normal and myelomatous plasma cell subsets
Clicks: 271
ID: 260081
2014
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
271 views
45 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #306 of 644 articles by views in sudebno-meditsinskaia ekspertiza
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 644 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Plasma-cells are essentially characterized by the co-expression of CD138 and CD38, which allows their identification in flow cytometry in bone marrow, peripheral blood or cell suspensions from tissues. These terminally differentiated B-cells may lose the expression of surface CD19 and that of CD20 while retaining CD27. When malignant, they can gain a number of other markers such as CD28, CD33, CD56 or CD117 and lose CD27. Moreover, since each plasma cell is only able to produce a single type of immunoglobulins, they display isotypic restriction and clonal malignant plasma cells can be further characterized by their homogeneous expression of either kappa or lambda light chains. In multiple myeloma (MM), such plasma cell clones produce the immunoglobulin identified in plasma as an abnormal peak. In the bone marrow where they essentially accumulate, these plasma cells may however display various immunophenotypes. The latter were explored in a two-way approach. Firstly the various subsets delineated by the selective or common expression of CD19 together with combined CD56/CD28 were explored in normal and MM bone marrow. Then other aberrant markers’ expression was investigated, i.e. CD20, CD27, CD33, CD56, CD117. These data were compared to literature information. They underline the vast heterogeneity of MM plasma cells possibly accounting for the various answers to therapy of MM patients.
| Reference Key |
erobillard2014frontiersimmunophenotype
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Nelly eRobillard;Soraya eWuillème;Philippe eMoreau;Marie C Bene |
| Journal | sudebno-meditsinskaia ekspertiza |
| Year | 2014 |
| DOI |
10.3389/fimmu.2014.00137
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.